NCT Number: NCT00116103
A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma
The purpose of this study is to determine the safety and effectiveness of tacrolimus inhalation aerosol in subjects with persistent asthma.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Scottsdale, Arizona, United States
About this study
The purpose of this randomized, double-blind, placebo-controlled, parallel-group, multi-center designed trial is to determine the safety and efficacy of tacrolimus inhalation aerosol in subjects with persistent asthma.
Who can participate
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Diagnosis of persistent asthma for at least 6 months
- Require use of beta-agonists at least four times per week
Exclusion criteria
- Diagnosis of chronic obstructive pulmonary disease (COPD)
Treatment and study plan
Primary outcomes
-
The primary outcome is the change in FEV1 from baseline to end-treatment.
Sponsors and collaborators
Lead sponsor
Astellas Pharma Inc
Industry
Collaborators
- Astellas Pharma US, Inc.
Registry information
Official study title
A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma
Important dates
- Study start
- 2005
- Study completion
- 2006
- First posted
- Jun 28, 2005
- Registry last updated
- Jun 7, 2012
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.
NCT03453112
Asthma, Bronchial Diseases
Hefei, Anhui, China
View Trial DetailsAgricultural Health Study Follow-up
NCT01399411
Asthma, Autoimmune Diseases
Iowa City, Illinois, United States
View Trial DetailsThe COX-2 Gene and the Immune System
NCT01678222
Allergic Inflammation, Asthma
Research Triangle Park, North Carolina, United States
View Trial DetailsSample Collections From the Airways of Asthmatic Patients
NCT00001888
Asthma, Bronchial Diseases
Bethesda, Maryland, United States
View Trial Details